Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lacey

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Plos Neglected Tropical Diseases|August 29, 2024
Development of a Core Outcome Measure Instrument; "LeishCOM_LCL", for Localised Cutaneous LeishmaniasisShalindra Ranasinghe, Sujai Senarathne, Vijani Somaratne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in SudanBrima M Younis, Mohamed Osman, Eltahir A G Khalil, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Immunity|December 21, 2017
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile AcidsWei Cao, Hisako Kayama, Mei Lan Chen, et al.
Plos Neglected Tropical Diseases|February 27, 2026
Systemic inflammatory markers of visceral leishmaniasis treatment response in East AfricaAyenew Addisu, Alice Bayiyana, João L Reis Cunha, et al.
Micropublication Biology|January 21, 2021
<i>B.2.16</i> is a non-lethal modifier of the <i>Dark</i> mosaic eye phenotype in <i>Drosophila melanogaster</i>Alysia D Vrailas-Mortimer, Nitish Aggarwal, Neha N Ahmed, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Plos Neglected Tropical Diseases|August 29, 2024
Development of a Core Outcome Measure Instrument; "LeishCOM_LCL", for Localised Cutaneous LeishmaniasisShalindra Ranasinghe, Sujai Senarathne, Vijani Somaratne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in SudanBrima M Younis, Mohamed Osman, Eltahir A G Khalil, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Immunity|December 21, 2017
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile AcidsWei Cao, Hisako Kayama, Mei Lan Chen, et al.
Plos Neglected Tropical Diseases|February 27, 2026
Systemic inflammatory markers of visceral leishmaniasis treatment response in East AfricaAyenew Addisu, Alice Bayiyana, João L Reis Cunha, et al.
Micropublication Biology|January 21, 2021
<i>B.2.16</i> is a non-lethal modifier of the <i>Dark</i> mosaic eye phenotype in <i>Drosophila melanogaster</i>Alysia D Vrailas-Mortimer, Nitish Aggarwal, Neha N Ahmed, et al.
Pageof 5